JP2012527407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527407A5 JP2012527407A5 JP2012511102A JP2012511102A JP2012527407A5 JP 2012527407 A5 JP2012527407 A5 JP 2012527407A5 JP 2012511102 A JP2012511102 A JP 2012511102A JP 2012511102 A JP2012511102 A JP 2012511102A JP 2012527407 A5 JP2012527407 A5 JP 2012527407A5
- Authority
- JP
- Japan
- Prior art keywords
- dynamin
- dynamin ring
- stabilizer
- ring
- podocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical group [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 46
- 239000003381 stabilizer Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 18
- 210000000557 podocyte Anatomy 0.000 claims 17
- 238000000034 method Methods 0.000 claims 10
- 108030002935 Dynamin GTPases Proteins 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 102000007469 Actins Human genes 0.000 claims 4
- 108010085238 Actins Proteins 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000043859 Dynamin Human genes 0.000 claims 3
- 108700021058 Dynamin Proteins 0.000 claims 3
- 229940123444 Dynamin inhibitor Drugs 0.000 claims 3
- 208000022461 Glomerular disease Diseases 0.000 claims 3
- 210000004292 cytoskeleton Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000001650 focal adhesion Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000007363 ring formation reaction Methods 0.000 claims 3
- WAVNYPVYNSIHNC-UHFFFAOYSA-N 2-benzylidenepropanedinitrile Chemical compound N#CC(C#N)=CC1=CC=CC=C1 WAVNYPVYNSIHNC-UHFFFAOYSA-N 0.000 claims 2
- -1 3-substituted naphthalene-2-carboxylic acids Chemical class 0.000 claims 2
- 229940122242 GTPase inhibitor Drugs 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- WUVFAMRFBRHSQW-UHFFFAOYSA-N chromen-2-imine Chemical class C1=CC=C2OC(=N)C=CC2=C1 WUVFAMRFBRHSQW-UHFFFAOYSA-N 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 231100000852 glomerular disease Toxicity 0.000 claims 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 206010060737 Congenital nephrotic syndrome Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000004132 Diffuse mesangial sclerosis Diseases 0.000 claims 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 201000004954 familial nephrotic syndrome Diseases 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 210000003518 stress fiber Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18026109P | 2009-05-21 | 2009-05-21 | |
| US61/180,261 | 2009-05-21 | ||
| PCT/AU2010/000677 WO2010132959A1 (en) | 2009-05-21 | 2010-05-21 | Use of dynamin ring stabilizers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527407A JP2012527407A (ja) | 2012-11-08 |
| JP2012527407A5 true JP2012527407A5 (enExample) | 2013-11-14 |
Family
ID=43125677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511102A Pending JP2012527407A (ja) | 2009-05-21 | 2010-05-21 | ダイナミン環安定剤の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8809386B2 (enExample) |
| EP (1) | EP2432465B1 (enExample) |
| JP (1) | JP2012527407A (enExample) |
| CN (1) | CN102481280A (enExample) |
| AU (1) | AU2010251703B2 (enExample) |
| BR (1) | BRPI1010941B1 (enExample) |
| CA (1) | CA2762600C (enExample) |
| WO (1) | WO2010132959A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782643A1 (en) * | 2011-11-23 | 2014-10-01 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Androgen receptor ligands |
| WO2014063205A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
| JP2017518312A (ja) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | マルメリン類似体および癌治療における使用方法 |
| CN105510592A (zh) * | 2014-09-26 | 2016-04-20 | 中国医学科学院基础医学研究所 | 梗阻性肾病的蛋白标志物 |
| US11028138B2 (en) * | 2016-07-02 | 2021-06-08 | Virongy L.L.C. | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |
| CN113801872A (zh) * | 2021-10-11 | 2021-12-17 | 杭州师范大学 | 一种精准调控组装制备稳定酶蛋白环的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107736A (en) | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
| WO2001064880A2 (en) | 2000-02-28 | 2001-09-07 | Millennium Pharmaceuticals, Inc. | Human dynamin 40322 |
| CN1938013A (zh) * | 2003-11-21 | 2007-03-28 | 纽卡斯尔大学研究协会有限公司 | 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂 |
| WO2005049009A1 (en) | 2003-11-21 | 2005-06-02 | The University Of Newcastle Research Associates Limited | Methods and agents for inhibiting dynamin-dependent endocytosis |
| WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| US9144594B2 (en) | 2005-11-08 | 2015-09-29 | University Of Miami | Cathepsin L mediated diseases and associated methods and products |
| WO2009034464A2 (en) | 2007-09-12 | 2009-03-19 | Newcastle Innovation Limited | Indole related compounds with physiological activity |
-
2010
- 2010-05-21 JP JP2012511102A patent/JP2012527407A/ja active Pending
- 2010-05-21 CN CN2010800333207A patent/CN102481280A/zh active Pending
- 2010-05-21 EP EP10777248.5A patent/EP2432465B1/en not_active Not-in-force
- 2010-05-21 BR BRPI1010941-2A patent/BRPI1010941B1/pt not_active IP Right Cessation
- 2010-05-21 AU AU2010251703A patent/AU2010251703B2/en not_active Ceased
- 2010-05-21 WO PCT/AU2010/000677 patent/WO2010132959A1/en not_active Ceased
- 2010-05-21 US US13/321,415 patent/US8809386B2/en active Active
- 2010-05-21 CA CA2762600A patent/CA2762600C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Ursolic acid attenuates diabetic mesangial cell injury through the up-regulation of autophagy via miRNA-21/PTEN/Akt/mTOR suppression | |
| Mielcarek et al. | HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy | |
| RU2015105893A (ru) | Ингибиторы цистатионин-г-лиазы (cse) | |
| CY1121601T1 (el) | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα | |
| Shan et al. | Epigenetic modification of miR-10a regulates renal damage by targeting CREB1 in type 2 diabetes mellitus | |
| JP2013516473A5 (enExample) | ||
| EP2588099A4 (en) | METHOD OF TREATING THE RESTLESS LEG SYNDROME | |
| EA201590040A1 (ru) | Получение, применение и твердые формы обетихолевой кислоты | |
| TW201641691A (zh) | Ｔａｕ反義寡聚物及其用途 | |
| PT2517700E (pt) | Cocristais farmaceuticamente aceitáveis de n-[2-(7-metoxi- 1-naftil)etil]acetamida e métodos para a sua preparação | |
| EA201001159A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| TR201909777T4 (tr) | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar | |
| MX2012015105A (es) | Inhibidores de cinasa de regulacion mediante señal de apoptosis. | |
| EP2823043A4 (en) | HIGHLY CONCENTRATED ALPHA-GLUCOSIDASE COMPOSITIONS FOR THE TREATMENT OF MORBUS POMPE | |
| JP2012093361A5 (enExample) | ||
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| EA201391584A1 (ru) | Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний | |
| EA201491247A1 (ru) | Производные дигидробензооксазина и дигидропиридооксазина | |
| EP3992183A4 (en) | METHODS OF TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | |
| EA201290860A1 (ru) | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата | |
| Tang et al. | HMGB1 mediates HAdV-7 infection-induced pulmonary inflammation in mice | |
| EA201201113A1 (ru) | Способы и соединения для роста мышц | |
| EA201001524A1 (ru) | Ингибиторы дезацетилазы в, основанные на гидроксамате | |
| RU2016145066A (ru) | Композиция для предотвращения или лечения жировых болезней печени | |
| JP2019524836A5 (enExample) |